Jun Miki

Jun Miki

Auto-generated profile, based on publicly available information

Jun Miki

Department of Urology, The Jikei University School of Medicine, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2022 in BJU International
Verified
Journal Article
Closed access
TYTakafumi Yanagisawa
Takafumi Yanagisawa
KMKeiichiro Mori
Keiichiro Mori
FQFahad Quhal
Fahad Quhal
TKTatsushi Kawada
Tatsushi Kawada
HMHadi Mostafaei
Hadi Mostafaei
SSShahrokh F. Shariat
Shahrokh F. Shariat

30 September 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Fumihiko UrabeFumihiko Urabe
Fumihiko Urabe
SKShoji Kimura
Shoji Kimura
KIKosuke Iwatani
Kosuke Iwatani
KTKazuhiro Takahashi
Kazuhiro Takahashi
KIKagenori Ito
Kagenori Ito
SEShin Egawa
Shin Egawa
Objective: To evaluate the risk factors of perioperative hemodynamic instability in pheochromocytoma, we conducted a systematic search of the literature using the Preferred Reporting Items for Systematic Reviews and Meta-analysis. Methods: In April 2021, we systematically searched PubMed, the Cochrane library, and Scopus for relevant studies on the risk factors of perioperative hemodynamic instability of adrenalectomy in patients with pheochromocytoma, and we subjected the findings from those studies to formal meta-analysis. Results: Our systematic review identified 14 studies involving 1725 patients, of which nine studies with 967 patients were eligible for meta-analysis. The results of meta-analysis showed that tumor size (odds ratio (OR): 1.14 for each increased cm, 95% confidence interval (CI) 1.03–1.26, z = 2.57) and urinary norepinephrine (OR, 1.51: 95% CI 1.26–1.81; z = 4.50) were most closely associated with the occurrence of perioperative hemodynamic instability. Conclusion: These findings suggest that tumor size and urinary norepinephrine are important predictors and risk factors for perioperative hemodynamic instability in adrenalectomy for pheochromocytoma. Such findings may be of value to surgeons and anesthesiologists when considering or preparing for this procedure.

25 January 2018 in The Prostate
Verified
Journal Article
Closed access
PDF file
JMJun Miki
Jun Miki
TYTakafumi Yanagisawa
Takafumi Yanagisawa
STShunsuke Tsuzuki
Shunsuke Tsuzuki
KMKeiichiro Mori
Keiichiro Mori
FUFumihiko Urabe
Fumihiko Urabe
SEShin Egawa
Shin Egawa

25 April 2022 in Immunotherapy
Verified
Journal Article
Closed access
TYTakafumi Yanagisawa
Takafumi Yanagisawa
KMKeiichiro Mori
Keiichiro Mori
SKSatoshi Katayama
Satoshi Katayama
HMHadi Mostafaei
Hadi Mostafaei
FQFahad Quhal
Fahad Quhal
SSShahrokh F. Shariat
Shahrokh F. Shariat
Aim: We aimed to assess the prognostic value of pretreatment hematological biomarkers in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICIs). Metho... Plain language summary Identifying the predictive/prognostic factors that can be applied to daily clinical practice is mandatory to facilitate the use of immune checkpoint inhibitors. Some pretreat...

17 November 2022 in Cancers
Verified
Journal Article
Open access
PDF file
YYYusuke Yano
Yusuke Yano
TOTakaya Ohno
Takaya Ohno
KKKazumasa Komura
Kazumasa Komura
WFWataru Fukuokaya
Wataru Fukuokaya
TUTaizo Uchimoto
Taizo Uchimoto
HAHaruhito Azuma
Haruhito Azuma
Serum C-reactive protein (CRP) is known to be a biomarker for systemic inflammatory reactions. In the present study, we sought to measure the predictive value of serum CRP level for metastatic renal cell carcinoma (mRCC) treated with first-line ipilimumab and nivolumab using our real-world clinical dataset including non-clear cell RCC (nccRCC). The clinical record of patients who underwent the first-line ipilimumab plus nivolumab treatment for mRCC including ccRCC and nccRCC from 2018 to 2021 was retrospectively analyzed. All patients were diagnosed with either intermediate or poor-risk group defined by IMCD (international metastatic RCC database consortium). In total, 74 patients were involved. The median age was 68 years and 24 (32.4%) patients deceased during the follow-up. Forty-five (61%) and 29 (39%) patients were classified into intermediate and poor-risk groups. The one-year overall survival (OS) rate and objective response rate were 65% and 41% for all 74 mRCC patients, respectively. The receiver operating characteristic curve identified 1.0 mg/dL of serum CRP level as an ideal cut-off for predicting overall survival (OS). Serum CRP > 1.0 mg/dL and nccRCC were the independent predictors for OS in 74 mRCC patients. OS for patients with CRP > 1 mg/dL was significantly shorter than those with CRP < 1 mg/dL in both ccRCC (58 patient: p = 0.009) and nccRCC (16 patients: p = 0.008). The present study indicated that serum CRP level is a prognostic indicator for OS in both ccRCC and nccRCC patients treated with the first-line ipilimumab plus nivolumab treatment.

24 September 2021 in The Prostate
Verified
Journal Article
Closed access
PDF file
TYTakafumi Yanagisawa
Takafumi Yanagisawa
TKTakahiro Kimura
Takahiro Kimura
KMKeiichiro Mori
Keiichiro Mori
HSHirotaka Suzuki
Hirotaka Suzuki
TSTakayuki Sano
Takayuki Sano
SEShin Egawa
Shin Egawa